Skip to main content
Top
Published in: Heart and Vessels 4/2017

01-04-2017 | Original Article

Are atherosclerotic risk factors associated with a poor prognosis in patients with hyperuricemic acute heart failure? The evaluation of the causal dependence of acute heart failure and hyperuricemia

Authors: Hirotake Okazaki, Akihiro Shirakabe, Nobuaki Kobayashi, Noritake Hata, Takuro Shinada, Masato Matsushita, Yoshiya Yamamoto, Yusaku Shibata, Junsuke Shibuya, Reiko Shiomura, Suguru Nishigoori, Kuniya Asai, Wataru Shimizu

Published in: Heart and Vessels | Issue 4/2017

Login to get access

Abstract

Atherosclerosis induces the elevation of uric acid (UA), and an elevated UA level is well known to lead to a poor prognosis in patients with acute heart failure (AHF). However, the prognostic value of atherosclerotic risk factors in hyperuricemic AHF patients remains to be elucidated. The data from 928 patients who were admitted to the intensive care unit (ICU) at Nippon Medical School Chiba Hokusoh Hospital between January 2001 and December 2014, and whose serum UA levels were measured were screened. A total of 394 AHF patients with hyperuricemia were enrolled in this study. The patients were assigned to a low-risk group (≤1 atherosclerosis risk factor) and a high-risk group (≥2 atherosclerosis risk factors) according to their number of risk factors. The patients in the low-risk group were more likely to have dilated cardiomyopathy, clinical scenario 3 than those in the high-risk group. The serum total bilirubin, blood urea nitrogen, C-reactive protein, and brain-type natriuretic peptide levels were significantly higher in the low-risk group than the high-risk group (p < 0.001, p = 0.005, p = 0.003, and p = 0.008, respectively). A multivariate Cox regression model revealed that the number of risk factors (number = 1, HR (hazard ratio) 0.243, 95 % CI 0.096–0.618, p = 0.003; number = 2, HR 0.253, 95 % CI 0.108–0.593, p = 0.002; number ≥3, HR 0.209, 95 % CI 0.093–0.472, p < 0.001), eGFR (per 1.0 mmol/l increase) (HR 0.977, 95 % CI 0.961–0.994, p = 0.007), and serum UA level (per 1 mg/dl increase) (HR 1.270, 95 % CI 1.123–1.435, p < 0.001) was an independent predictor of 1-year mortality. The prognosis, including all-cause death and HF events, was significantly poorer among the low-risk patients than among the high-risk patients. Atherosclerotic risk factors were not associated with a poor prognosis in patients with hyperuricemic AHF.
Literature
1.
go back to reference Grayson PC, Kim SY, LaValley M, Choi HK (2011) Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 63:102–110CrossRef Grayson PC, Kim SY, LaValley M, Choi HK (2011) Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 63:102–110CrossRef
2.
go back to reference Lv Q, Meng XF, He FF, Chen S, Su H, Xiong J, Gao P, Tian XJ, Liu JS, Zhu ZH, Huang K, Zhang C (2013) High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies. PLoS One 8:e56864CrossRefPubMedPubMedCentral Lv Q, Meng XF, He FF, Chen S, Su H, Xiong J, Gao P, Tian XJ, Liu JS, Zhu ZH, Huang K, Zhang C (2013) High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies. PLoS One 8:e56864CrossRefPubMedPubMedCentral
4.
go back to reference Huang H, Huang B, Li Y, Huang Y, Li J, Yao H, Jing X, Chen J, Wang J (2014) Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail 16:15–24CrossRefPubMed Huang H, Huang B, Li Y, Huang Y, Li J, Yao H, Jing X, Chen J, Wang J (2014) Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail 16:15–24CrossRefPubMed
5.
go back to reference Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, Davos CH, Cicoira M, Shamim W, Kemp M, Segal R, Osterziel KJ, Leyva F, Hetzer R, Ponikowski P, Coats AJ (2003) Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 107:1991–1997CrossRefPubMed Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, Davos CH, Cicoira M, Shamim W, Kemp M, Segal R, Osterziel KJ, Leyva F, Hetzer R, Ponikowski P, Coats AJ (2003) Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 107:1991–1997CrossRefPubMed
6.
go back to reference Huang WM, Hsu PF, Cheng HM, Lu DY, Cheng YL, Guo CY, Sung SH, Yu WC, Chen CH (2016) Determinants and prognostic impact of hyperuricemia in hospitalization for acute heart failure. Circ J 80:404–410CrossRefPubMed Huang WM, Hsu PF, Cheng HM, Lu DY, Cheng YL, Guo CY, Sung SH, Yu WC, Chen CH (2016) Determinants and prognostic impact of hyperuricemia in hospitalization for acute heart failure. Circ J 80:404–410CrossRefPubMed
7.
go back to reference Tamariz L, Harzand A, Palacio A, Verma S, Jones J, Hare J (2011) Uric acid as a predictor of all-cause mortality in heart failure: a meta-analysis. Congest Heart Fail 17:25–30CrossRefPubMed Tamariz L, Harzand A, Palacio A, Verma S, Jones J, Hare J (2011) Uric acid as a predictor of all-cause mortality in heart failure: a meta-analysis. Congest Heart Fail 17:25–30CrossRefPubMed
8.
go back to reference Okazaki H, Shirakabe A, Kobayashi N, Hata N, Shinada T, Matsushita M, Yamamoto Y, Shibuya J, Shiomura R, Nishigoori S, Asai K, Shimizu W (2016) The prognostic impact of uric acid in patients with severely decompensated acute heart failure. J Cardiol. doi:10.1016/j.jjcc.2016.04.013 Okazaki H, Shirakabe A, Kobayashi N, Hata N, Shinada T, Matsushita M, Yamamoto Y, Shibuya J, Shiomura R, Nishigoori S, Asai K, Shimizu W (2016) The prognostic impact of uric acid in patients with severely decompensated acute heart failure. J Cardiol. doi:10.​1016/​j.​jjcc.​2016.​04.​013
9.
go back to reference Gheorghiade M, Zannad F, Sopko G, Klein L, Pina IL, Konstam MA, Massie BM, Roland E, Targum S, Collins SP, Filippatos G, Tavazzi L (2005) Acute heart failure syndromes: current state and framework for future research. Circulation 112:3958–3968CrossRefPubMed Gheorghiade M, Zannad F, Sopko G, Klein L, Pina IL, Konstam MA, Massie BM, Roland E, Targum S, Collins SP, Filippatos G, Tavazzi L (2005) Acute heart failure syndromes: current state and framework for future research. Circulation 112:3958–3968CrossRefPubMed
10.
go back to reference Nieminen MS, Harjola VP (2005) Definition and epidemiology of acute heart failure syndromes. Am J Cardiol 96:5g–10gCrossRefPubMed Nieminen MS, Harjola VP (2005) Definition and epidemiology of acute heart failure syndromes. Am J Cardiol 96:5g–10gCrossRefPubMed
11.
go back to reference McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33:1787–1847CrossRefPubMed McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33:1787–1847CrossRefPubMed
12.
go back to reference Yamanaka H, Metabolism TG (2012) Essence of the revised guideline for the management of hyperuricemia and gout. Japan Med Assoc J 55:324–329PubMed Yamanaka H, Metabolism TG (2012) Essence of the revised guideline for the management of hyperuricemia and gout. Japan Med Assoc J 55:324–329PubMed
13.
go back to reference Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, Daida H, Biro S, Hirobe K, Funahashi T, Yokote K, Yokode M, Japan Atherosclerosis Society Committee for E, Clinical Management of A (2007) Diagnostic criteria for dyslipidemia. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 14:155–158CrossRefPubMed Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, Daida H, Biro S, Hirobe K, Funahashi T, Yokote K, Yokode M, Japan Atherosclerosis Society Committee for E, Clinical Management of A (2007) Diagnostic criteria for dyslipidemia. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 14:155–158CrossRefPubMed
14.
go back to reference Mebazaa A, Gheorghiade M, Pina IL, Harjola VP, Hollenberg SM, Follath F, Rhodes A, Plaisance P, Roland E, Nieminen M, Komajda M, Parkhomenko A, Masip J, Zannad F, Filippatos G (2008) Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med 36:S129–139CrossRefPubMed Mebazaa A, Gheorghiade M, Pina IL, Harjola VP, Hollenberg SM, Follath F, Rhodes A, Plaisance P, Roland E, Nieminen M, Komajda M, Parkhomenko A, Masip J, Zannad F, Filippatos G (2008) Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med 36:S129–139CrossRefPubMed
16.
go back to reference Hamaguchi S, Furumoto T, Tsuchihashi-Makaya M, Goto K, Goto D, Yokota T, Kinugawa S, Yokoshiki H, Takeshita A, Tsutsui H, Investigators JC (2011) Hyperuricemia predicts adverse outcomes in patients with heart failure. Int J Cardiol 151:143–147CrossRefPubMed Hamaguchi S, Furumoto T, Tsuchihashi-Makaya M, Goto K, Goto D, Yokota T, Kinugawa S, Yokoshiki H, Takeshita A, Tsutsui H, Investigators JC (2011) Hyperuricemia predicts adverse outcomes in patients with heart failure. Int J Cardiol 151:143–147CrossRefPubMed
17.
go back to reference Mandviwala T, Khalid U, Deswal A (2016) Obesity and cardiovascular disease: a risk factor or a risk marker? Curr Atheroscler Rep 18:21CrossRefPubMed Mandviwala T, Khalid U, Deswal A (2016) Obesity and cardiovascular disease: a risk factor or a risk marker? Curr Atheroscler Rep 18:21CrossRefPubMed
18.
go back to reference Kaul S, Alladi S, Mridula RK, Bandaru SV, Boddu DB, Anjanikumar D, Umamashesh M (2015) Prevalence and risk factors of carotid intima-media thickness in asymptomatic individual subjects in a tertiary care center in India. Ann Indian Acad Neurol 18:430–434PubMedPubMedCentral Kaul S, Alladi S, Mridula RK, Bandaru SV, Boddu DB, Anjanikumar D, Umamashesh M (2015) Prevalence and risk factors of carotid intima-media thickness in asymptomatic individual subjects in a tertiary care center in India. Ann Indian Acad Neurol 18:430–434PubMedPubMedCentral
19.
go back to reference Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847CrossRefPubMed Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847CrossRefPubMed
20.
go back to reference Kondo T, Yamada T, Morita T, Furukawa Y, Tamaki S, Iwasaki Y, Kawasaki M, Kikuchi A, Kawai T, Takahashi S, Ishimi M, Hakui H, Ozaki T, Sato Y, Seo M, Sakata Y, Fukunami M (2016) The CHADS2 score predicts ischemic stroke in chronic heart failure patients without atrial fibrillation: comparison to other stroke risk scores. Heart Vessels. doi:10.1007/s00380-016-0861-7 Kondo T, Yamada T, Morita T, Furukawa Y, Tamaki S, Iwasaki Y, Kawasaki M, Kikuchi A, Kawai T, Takahashi S, Ishimi M, Hakui H, Ozaki T, Sato Y, Seo M, Sakata Y, Fukunami M (2016) The CHADS2 score predicts ischemic stroke in chronic heart failure patients without atrial fibrillation: comparison to other stroke risk scores. Heart Vessels. doi:10.​1007/​s00380-016-0861-7
21.
go back to reference Hanatani A, Shibata A, Kitada R, Iwata S, Matsumura Y, Doi A, Sugioka K, Takagi M, Yoshiyama M (2016) Administration of tolvaptan with reduction of loop diuretics ameliorates congestion with improving renal dysfunction in patients with congestive heart failure and renal dysfunction. Heart Vessels. doi:10.1007/s00380-016-0872-4 Hanatani A, Shibata A, Kitada R, Iwata S, Matsumura Y, Doi A, Sugioka K, Takagi M, Yoshiyama M (2016) Administration of tolvaptan with reduction of loop diuretics ameliorates congestion with improving renal dysfunction in patients with congestive heart failure and renal dysfunction. Heart Vessels. doi:10.​1007/​s00380-016-0872-4
22.
go back to reference Shirakabe A, Hata N, Kobayashi N, Okazaki H, Shinada T, Tomita K, Yamamoto M, Tsurumi M, Matsushita M, Yamamoto Y, Yokoyama S, Asai K, Shimizu W (2015) Serum heart-type fatty acid-binding protein level can be used to detect acute kidney injury on admission and predict an adverse outcome in patients with acute heart failure. Circ J 79:119–128CrossRefPubMed Shirakabe A, Hata N, Kobayashi N, Okazaki H, Shinada T, Tomita K, Yamamoto M, Tsurumi M, Matsushita M, Yamamoto Y, Yokoyama S, Asai K, Shimizu W (2015) Serum heart-type fatty acid-binding protein level can be used to detect acute kidney injury on admission and predict an adverse outcome in patients with acute heart failure. Circ J 79:119–128CrossRefPubMed
23.
go back to reference Shirakabe A, Hata N, Kobayashi N, Shinada T, Tomita K, Tsurumi M, Matsushita M, Okazaki H, Yamamoto Y, Yokoyama S, Asai K, Mizuno K (2013) Prognostic impact of acute kidney injury in patients with acute decompensated heart failure. Circ J 77:687–696CrossRefPubMed Shirakabe A, Hata N, Kobayashi N, Shinada T, Tomita K, Tsurumi M, Matsushita M, Okazaki H, Yamamoto Y, Yokoyama S, Asai K, Mizuno K (2013) Prognostic impact of acute kidney injury in patients with acute decompensated heart failure. Circ J 77:687–696CrossRefPubMed
24.
go back to reference Schrier RW (2006) Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor? J Am Coll Cardiol 47:1–8CrossRefPubMed Schrier RW (2006) Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor? J Am Coll Cardiol 47:1–8CrossRefPubMed
25.
go back to reference Schrier RW, Abraham WT (1999) Hormones and hemodynamics in heart failure. N Engl J Med 341:577–585CrossRefPubMed Schrier RW, Abraham WT (1999) Hormones and hemodynamics in heart failure. N Engl J Med 341:577–585CrossRefPubMed
26.
go back to reference Aronson D, Mittleman MA, Burger AJ (2004) Elevated blood urea nitrogen level as a predictor of mortality in patients admitted for decompensated heart failure. Am J Med 116:466–473CrossRefPubMed Aronson D, Mittleman MA, Burger AJ (2004) Elevated blood urea nitrogen level as a predictor of mortality in patients admitted for decompensated heart failure. Am J Med 116:466–473CrossRefPubMed
Metadata
Title
Are atherosclerotic risk factors associated with a poor prognosis in patients with hyperuricemic acute heart failure? The evaluation of the causal dependence of acute heart failure and hyperuricemia
Authors
Hirotake Okazaki
Akihiro Shirakabe
Nobuaki Kobayashi
Noritake Hata
Takuro Shinada
Masato Matsushita
Yoshiya Yamamoto
Yusaku Shibata
Junsuke Shibuya
Reiko Shiomura
Suguru Nishigoori
Kuniya Asai
Wataru Shimizu
Publication date
01-04-2017
Publisher
Springer Japan
Published in
Heart and Vessels / Issue 4/2017
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-016-0893-z

Other articles of this Issue 4/2017

Heart and Vessels 4/2017 Go to the issue